Review



monoclonal antibody mab alone  (Bio X Cell)


Bioz Verified Symbol Bio X Cell is a verified supplier
Bioz Manufacturer Symbol Bio X Cell manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 99
      Buy from Supplier

    Structured Review

    Bio X Cell monoclonal antibody mab alone
    SLC1A5 knockout in T cells enhances the therapeutic efficacy of anti-PD1 in mice. A IDO1-overexpressing LLC cells were injected into SLC1A5 fl/fl or SLC1A5 CKO mice through the tail vein, followed by treatment with anti-PD-1 <t>monoclonal</t> antibody (mAb) or control IgG. B Number of metastatic nodules formed by LLC cells in the lungs of mice. C Kaplan–Meier survival analysis of the mice. D GFP-IDO1-overexpressing LLC cells were implanted into C57BL/6 mice, followed by treatment with V-9302 (an SLC1A5 inhibitor), anti-PD-1 mAb, or a combination of both. E – F Analysis of bioluminescence intensity in the mice at 7, 14, and 28 d post-treatment. G-H. FACS analysis of the number of GZMB + CD8 + ( G ) and TNFA + CD8 + ( H ) T cells in tumor tissues. I FACS analysis of the number of TEX (PD1 + TIM3 + ) and TPEX (PD1 + TIM3. − ) cells in LLC-induced tumors. J Kaplan–Meier survival analysis of the mice. Animal experiments involved six mice per group. Data are presented as dot plots and bars. Statistical significance was set at p < 0.05
    Monoclonal Antibody Mab Alone, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 99/100, based on 1103 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/monoclonal+antibody+mab+alone/pmc13014849-132-27-31?v=Bio+X+Cell
    Average 99 stars, based on 1103 article reviews
    monoclonal antibody mab alone - by Bioz Stars, 2026-07
    99/100 stars

    Images

    1) Product Images from "SLC1A5-mediated kynurenine metabolism drives AHR-FANCD2 axis to remodel chromatin and induce T cell exhaustion in lung adenocarcinoma"

    Article Title: SLC1A5-mediated kynurenine metabolism drives AHR-FANCD2 axis to remodel chromatin and induce T cell exhaustion in lung adenocarcinoma

    Journal: Cell Communication and Signaling : CCS

    doi: 10.1186/s12964-026-02732-3

    SLC1A5 knockout in T cells enhances the therapeutic efficacy of anti-PD1 in mice. A IDO1-overexpressing LLC cells were injected into SLC1A5 fl/fl or SLC1A5 CKO mice through the tail vein, followed by treatment with anti-PD-1 monoclonal antibody (mAb) or control IgG. B Number of metastatic nodules formed by LLC cells in the lungs of mice. C Kaplan–Meier survival analysis of the mice. D GFP-IDO1-overexpressing LLC cells were implanted into C57BL/6 mice, followed by treatment with V-9302 (an SLC1A5 inhibitor), anti-PD-1 mAb, or a combination of both. E – F Analysis of bioluminescence intensity in the mice at 7, 14, and 28 d post-treatment. G-H. FACS analysis of the number of GZMB + CD8 + ( G ) and TNFA + CD8 + ( H ) T cells in tumor tissues. I FACS analysis of the number of TEX (PD1 + TIM3 + ) and TPEX (PD1 + TIM3. − ) cells in LLC-induced tumors. J Kaplan–Meier survival analysis of the mice. Animal experiments involved six mice per group. Data are presented as dot plots and bars. Statistical significance was set at p < 0.05
    Figure Legend Snippet: SLC1A5 knockout in T cells enhances the therapeutic efficacy of anti-PD1 in mice. A IDO1-overexpressing LLC cells were injected into SLC1A5 fl/fl or SLC1A5 CKO mice through the tail vein, followed by treatment with anti-PD-1 monoclonal antibody (mAb) or control IgG. B Number of metastatic nodules formed by LLC cells in the lungs of mice. C Kaplan–Meier survival analysis of the mice. D GFP-IDO1-overexpressing LLC cells were implanted into C57BL/6 mice, followed by treatment with V-9302 (an SLC1A5 inhibitor), anti-PD-1 mAb, or a combination of both. E – F Analysis of bioluminescence intensity in the mice at 7, 14, and 28 d post-treatment. G-H. FACS analysis of the number of GZMB + CD8 + ( G ) and TNFA + CD8 + ( H ) T cells in tumor tissues. I FACS analysis of the number of TEX (PD1 + TIM3 + ) and TPEX (PD1 + TIM3. − ) cells in LLC-induced tumors. J Kaplan–Meier survival analysis of the mice. Animal experiments involved six mice per group. Data are presented as dot plots and bars. Statistical significance was set at p < 0.05

    Techniques Used: Knock-Out, Drug discovery, Injection, Control



    Similar Products

    monoclonal antibody mab alone  (Bio X Cell)
    99
    Bio X Cell monoclonal antibody mab alone
    SLC1A5 knockout in T cells enhances the therapeutic efficacy of anti-PD1 in mice. A IDO1-overexpressing LLC cells were injected into SLC1A5 fl/fl or SLC1A5 CKO mice through the tail vein, followed by treatment with anti-PD-1 <t>monoclonal</t> antibody (mAb) or control IgG. B Number of metastatic nodules formed by LLC cells in the lungs of mice. C Kaplan–Meier survival analysis of the mice. D GFP-IDO1-overexpressing LLC cells were implanted into C57BL/6 mice, followed by treatment with V-9302 (an SLC1A5 inhibitor), anti-PD-1 mAb, or a combination of both. E – F Analysis of bioluminescence intensity in the mice at 7, 14, and 28 d post-treatment. G-H. FACS analysis of the number of GZMB + CD8 + ( G ) and TNFA + CD8 + ( H ) T cells in tumor tissues. I FACS analysis of the number of TEX (PD1 + TIM3 + ) and TPEX (PD1 + TIM3. − ) cells in LLC-induced tumors. J Kaplan–Meier survival analysis of the mice. Animal experiments involved six mice per group. Data are presented as dot plots and bars. Statistical significance was set at p < 0.05
    Monoclonal Antibody Mab Alone, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/monoclonal+antibody+mab+alone/pmc13014849-132-27-31?v=Bio+X+Cell
    Average 99 stars, based on 1 article reviews
    monoclonal antibody mab alone - by Bioz Stars, 2026-07
    99/100 stars
    		  Buy from Supplier
    nzv930 a monoclonal antibody alone  (Novartis)
    86
    Novartis nzv930 a monoclonal antibody alone
    SLC1A5 knockout in T cells enhances the therapeutic efficacy of anti-PD1 in mice. A IDO1-overexpressing LLC cells were injected into SLC1A5 fl/fl or SLC1A5 CKO mice through the tail vein, followed by treatment with anti-PD-1 <t>monoclonal</t> antibody (mAb) or control IgG. B Number of metastatic nodules formed by LLC cells in the lungs of mice. C Kaplan–Meier survival analysis of the mice. D GFP-IDO1-overexpressing LLC cells were implanted into C57BL/6 mice, followed by treatment with V-9302 (an SLC1A5 inhibitor), anti-PD-1 mAb, or a combination of both. E – F Analysis of bioluminescence intensity in the mice at 7, 14, and 28 d post-treatment. G-H. FACS analysis of the number of GZMB + CD8 + ( G ) and TNFA + CD8 + ( H ) T cells in tumor tissues. I FACS analysis of the number of TEX (PD1 + TIM3 + ) and TPEX (PD1 + TIM3. − ) cells in LLC-induced tumors. J Kaplan–Meier survival analysis of the mice. Animal experiments involved six mice per group. Data are presented as dot plots and bars. Statistical significance was set at p < 0.05
    Nzv930 A Monoclonal Antibody Alone, supplied by Novartis, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/monoclonal+antibody+mab+alone/pmc12171894-92-21-1?v=Novartis
    Average 86 stars, based on 1 article reviews
    nzv930 a monoclonal antibody alone - by Bioz Stars, 2026-07
    86/100 stars
    		  Buy from Supplier

    Image Search Results


    SLC1A5 knockout in T cells enhances the therapeutic efficacy of anti-PD1 in mice. A IDO1-overexpressing LLC cells were injected into SLC1A5 fl/fl or SLC1A5 CKO mice through the tail vein, followed by treatment with anti-PD-1 monoclonal antibody (mAb) or control IgG. B Number of metastatic nodules formed by LLC cells in the lungs of mice. C Kaplan–Meier survival analysis of the mice. D GFP-IDO1-overexpressing LLC cells were implanted into C57BL/6 mice, followed by treatment with V-9302 (an SLC1A5 inhibitor), anti-PD-1 mAb, or a combination of both. E – F Analysis of bioluminescence intensity in the mice at 7, 14, and 28 d post-treatment. G-H. FACS analysis of the number of GZMB + CD8 + ( G ) and TNFA + CD8 + ( H ) T cells in tumor tissues. I FACS analysis of the number of TEX (PD1 + TIM3 + ) and TPEX (PD1 + TIM3. − ) cells in LLC-induced tumors. J Kaplan–Meier survival analysis of the mice. Animal experiments involved six mice per group. Data are presented as dot plots and bars. Statistical significance was set at p < 0.05

    Journal: Cell Communication and Signaling : CCS

    Article Title: SLC1A5-mediated kynurenine metabolism drives AHR-FANCD2 axis to remodel chromatin and induce T cell exhaustion in lung adenocarcinoma

    doi: 10.1186/s12964-026-02732-3

    Figure Lengend Snippet: SLC1A5 knockout in T cells enhances the therapeutic efficacy of anti-PD1 in mice. A IDO1-overexpressing LLC cells were injected into SLC1A5 fl/fl or SLC1A5 CKO mice through the tail vein, followed by treatment with anti-PD-1 monoclonal antibody (mAb) or control IgG. B Number of metastatic nodules formed by LLC cells in the lungs of mice. C Kaplan–Meier survival analysis of the mice. D GFP-IDO1-overexpressing LLC cells were implanted into C57BL/6 mice, followed by treatment with V-9302 (an SLC1A5 inhibitor), anti-PD-1 mAb, or a combination of both. E – F Analysis of bioluminescence intensity in the mice at 7, 14, and 28 d post-treatment. G-H. FACS analysis of the number of GZMB + CD8 + ( G ) and TNFA + CD8 + ( H ) T cells in tumor tissues. I FACS analysis of the number of TEX (PD1 + TIM3 + ) and TPEX (PD1 + TIM3. − ) cells in LLC-induced tumors. J Kaplan–Meier survival analysis of the mice. Animal experiments involved six mice per group. Data are presented as dot plots and bars. Statistical significance was set at p < 0.05

    Article Snippet: In the immunotherapy experiment, mice were randomly assigned to receive the following treatments: PBS, SLC1A5 small molecule inhibitor V-9302 (60 mg/kg, oral gavage daily), IgG control, PD-1 monoclonal antibody (mAb) alone (BioXcell, BE0146, 200 μg, intraperitoneal injection every other day), or the combination of V-9302 and the PD-1 mAb.

    Techniques: Knock-Out, Drug discovery, Injection, Control